NASDAQ:ELUT Elutia (ELUT) Stock Price, News & Analysis → What Nvidia insiders don’t want you to know (From Behind the Markets) (Ad) Free ELUT Stock Alerts $3.48 +0.08 (+2.35%) (As of 02:33 PM ET) Add Compare Share Share Today's Range$3.32▼$3.4850-Day Range$2.77▼$3.4252-Week Range$1.10▼$4.19Volume2,584 shsAverage Volume20,122 shsMarket Capitalization$84.47 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Elutia alerts: Email Address Elutia MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside43.7% Upside$5.00 Price TargetShort InterestHealthy0.16% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.33 out of 5 starsMedical Sector465th out of 905 stocksBiological Products, Except Diagnostic Industry66th out of 150 stocks 3.5 Analyst's Opinion Consensus RatingElutia has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageElutia has only been the subject of 1 research reports in the past 90 days.Read more about Elutia's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.16% of the float of Elutia has been sold short.Short Interest Ratio / Days to CoverElutia has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Elutia has recently decreased by 23.32%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldElutia does not currently pay a dividend.Dividend GrowthElutia does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ELUT. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Elutia this week, compared to 1 article on an average week.MarketBeat Follows2 people have added Elutia to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Elutia insiders have not sold or bought any company stock.Percentage Held by Insiders40.80% of the stock of Elutia is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions74.03% of the stock of Elutia is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Elutia's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Elutia is -1.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Elutia is -1.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Elutia's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsMissed Nvidia? Don't Worry…If you missed out on Nvidia, don't worry. A 244-year-old pattern is about to trigger a $25.6 trillion AI surge... And send three overlooked stocks soaring 1,000%+Get my new research on all three plays right now. About Elutia Stock (NASDAQ:ELUT)Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.Read More ELUT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ELUT Stock News HeadlinesMay 13, 2024 | finance.yahoo.comElutia to Showcase BioEnvelope Product Line at Heart Rhythm 2024May 10, 2024 | investorplace.comELUT Stock Earnings: Elutia Misses EPS, Beats Revenue for Q1 2024May 9, 2024 | finance.yahoo.comElutia Announces First Quarter 2024 Results: SimpliDerm® Sales Increase 55%, CanGaroo®RM on Track for Second Quarter 2024 FDA ClearanceMay 2, 2024 | finance.yahoo.comElutia to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024April 24, 2024 | globenewswire.comElutia to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1March 10, 2024 | finanznachrichten.deElutia Inc.: Elutia Reports Fourth Quarter and Full Year 2023 Financial Results: Anticipates CanGarooRM Clearance Decision in First Half of 2024March 10, 2024 | finance.yahoo.comElutia Full Year 2023 Earnings: Misses ExpectationsMarch 8, 2024 | finance.yahoo.comQ4 2023 Elutia Inc Earnings CallMarch 7, 2024 | investorplace.comELUT Stock Earnings: Elutia Misses EPS, Misses Revenue for Q4 2023March 7, 2024 | benzinga.comRecap: Elutia Q4 EarningsMarch 7, 2024 | globenewswire.comElutia Reports Fourth Quarter and Full Year 2023 Financial Results: Anticipates CanGarooRM® Clearance Decision in First Half of 2024March 6, 2024 | benzinga.comPreview: Elutia's EarningsFebruary 22, 2024 | globenewswire.comElutia to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 7, 2024February 22, 2024 | finance.yahoo.comUmoja Biopharma to Participate in a Fireside Chat at the Evercore ISI 2024 Emerging Biotech ConferenceFebruary 21, 2024 | finance.yahoo.comCalliditas Year-end report, January - December 2023February 11, 2024 | wsj.comElutia Inc.February 9, 2024 | proactiveinvestors.comElutia's CanGarooRM: Pioneering Drug-Eluting Biologic for Secure Medical ImplantsFebruary 4, 2024 | msn.comAziyo Biologics Announces Executive Compensation AdjustmentsJanuary 11, 2024 | finanznachrichten.deElutia Inc.: Elutia Regains Compliance with Nasdaq Listing RequirementsJanuary 10, 2024 | msn.comElutia regains compliance with NasdaqJanuary 10, 2024 | finance.yahoo.comElutia Regains Compliance with Nasdaq Listing RequirementsJanuary 10, 2024 | finance.yahoo.comElutia Inc. (ELUT) Stock Historical Prices & Data - Yahoo FinanceJanuary 2, 2024 | bizjournals.comSilver Spring regenerative medicine firm Elutia regains Nasdaq compliance as business prospects brightenDecember 18, 2023 | finance.yahoo.comElutia Submits CanGarooRM® Antibiotic-Eluting Biomatrix for FDA ClearanceNovember 20, 2023 | msn.comElutia files to sell 18.58M shares of Class A common stock for holdersSee More Headlines Receive ELUT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Elutia and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/07/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ELUT CUSIPN/A CIK1708527 Webwww.elutia.com Phone240-247-1170Fax510-307-9896Employees54Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+47.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,660,000.00 Net Margins-164.45% Pretax Margin-170.52% Return on EquityN/A Return on Assets-112.77% Debt Debt-to-Equity RatioN/A Current Ratio0.63 Quick Ratio0.55 Sales & Book Value Annual Sales$25.05 million Price / Sales3.29 Cash FlowN/A Price / Cash FlowN/A Book Value($1.66) per share Price / Book-2.05Miscellaneous Outstanding Shares24,273,000Free Float14,370,000Market Cap$82.53 million OptionableNot Optionable Beta0.61 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. C. Randal Mills Ph.D. (Age 52)Co-Founder, President & CEO and Director Comp: $857.26kMr. Matthew B. Ferguson (Age 56)Chief Financial Officer Comp: $360.65kMs. Erica ElchinVice President of Global OperationsDr. Michelle LeRoux Williams Ph.D. (Age 49)Chief Scientific Officer Ms. Courtney GuyerVice President of MarketingDr. Sonali Fonseca Ph.D.VP & Head of Emerging BusinessesMr. Jeffry D. HametSenior VP of Finance, Treasurer & SecretaryMore ExecutivesKey CompetitorsMeiraGTxNASDAQ:MGTXPoseida TherapeuticsNASDAQ:PSTXAdaptimmune TherapeuticsNASDAQ:ADAPBlack Diamond TherapeuticsNASDAQ:BDTXCandel TherapeuticsNASDAQ:CADLView All CompetitorsInstitutional OwnershipPerkins Capital Management Inc.Bought 797,602 shares on 5/10/2024Ownership: 3.286%Verdence Capital Advisors LLCBought 14,410 shares on 4/26/2024Ownership: 0.059%View All Institutional Transactions ELUT Stock Analysis - Frequently Asked Questions Should I buy or sell Elutia stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Elutia in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ELUT shares. View ELUT analyst ratings or view top-rated stocks. What is Elutia's stock price target for 2024? 2 brokers have issued 12 month price objectives for Elutia's shares. Their ELUT share price targets range from $5.00 to $5.00. On average, they anticipate the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 43.7% from the stock's current price. View analysts price targets for ELUT or view top-rated stocks among Wall Street analysts. How have ELUT shares performed in 2024? Elutia's stock was trading at $2.16 at the beginning of 2024. Since then, ELUT shares have increased by 61.1% and is now trading at $3.48. View the best growth stocks for 2024 here. Are investors shorting Elutia? Elutia saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 19,400 shares, a decline of 23.3% from the April 30th total of 25,300 shares. Based on an average daily trading volume, of 14,700 shares, the days-to-cover ratio is presently 1.3 days. Currently, 0.2% of the company's shares are sold short. View Elutia's Short Interest. When is Elutia's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our ELUT earnings forecast. How were Elutia's earnings last quarter? Elutia Inc. (NASDAQ:ELUT) released its quarterly earnings data on Thursday, May, 9th. The company reported ($0.75) EPS for the quarter. The company had revenue of $6.69 million for the quarter. Who are Elutia's major shareholders? Elutia's stock is owned by a number of institutional and retail investors. Top institutional investors include Perkins Capital Management Inc. (3.29%) and Verdence Capital Advisors LLC (0.06%). Insiders that own company stock include Birchview Capital, Lp, Brigid Makes, David Colpman, Highcape Capital, LP, Matthew Ferguson and Thomas Englese. View institutional ownership trends. How do I buy shares of Elutia? Shares of ELUT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ELUT) was last updated on 6/7/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s Final Masterpiece: “X-9840”The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Ju...Paradigm Press | SponsoredWhat Nvidia insiders don’t want you to knowIf you missed out on Nvidia, don't worry. A 244-year-old pattern is about to trigger a $25.6 trillion AI surge...Behind the Markets | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elutia Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elutia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
